Bayer AG (BAYRY) recently announced that a phase III trial of Nexavar (sorafenib), co-developed and marketed with Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), failed to meet the primary endpoint.
The MISSION (Monotherapy administration of Sorafenib in patients with non-small cell lung cancer) trial was designed to evaluate Nexavar plus best supportive care versus placebo plus best supportive care in treatment-experienced patients with advanced relapsed or refractory non-squamous non-small cell lung … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards